BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
A molecular link between the active component of marijuana and Alzheimer’s disease pathology.
Authors: Lisa M. Eubanks, Claude J. Rogers, George F. Koob, Arthur J. Olson, Tobin J. Dickerson, Kim D. Janda
Molecular Pharmaceutics, 2006
—
Alzheimer’s disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer’s disease are expected to triple over the next 50 years. Consequently, the development of treatments that slow or halt the disease p…
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.
Authors: D. R. Blake, P. Robson, M. Ho, R. W. Jubb, C. S. McCabe
Rheumatology, January 2006
—
OBJECTIVES: To assess the efficacy of a cannabis-based medicine (CBM) in the treatment of pain due to rheumatoid arthritis (RA). METHODS: We compared a CBM (Sativex) with placebo in a randomized, double-blind, parallel group study in 58 patients over 5 weeks of treatment. The…
Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.
Authors: Kahlid Salim, Udo Schneider, Sumner Burstein, Ludwig Hoy, Matthias Karst
Neuropharmacology, June 2005
—
Preclinical findings on ajulemic acid (AJA) showed analgesic and anti-allodynic effects without psychoactive properties making it an appealing substance for the treatment of pain. A recently published randomized double-blind crossover clinical trial described the pain-reducing…
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.
Authors: C. H. Ashton, P. B. Moore, P. Gallagher, A. H. Young
Journal of Psychopharmacology, May 2005
—
Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of can…
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.
Authors: Angelo Vaccani, Paola Massi, Arianna Colombo, Tiziana Rubino, Daniela Parolaro
British Journal of Pharmacology, April 2005
—
We evaluated the ability of cannabidiol (CBD) to impair the migration of tumor cells stimulated by conditioned medium. CBD caused concentration-dependent inhibition of the migration of U87 glioma cells, quantified in a Boyden chamber. Since these cells express both cannabinoid…
Cardiovascular pharmacology of cannabinoids.
Authors: P. Pacher, S. Bátkai, G. Kunos
Handbook of Experimental Pharmacology, 2005
—
Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in…
Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.
Authors: J H Allen, G M de Moore, R Heddle, J C Twartz
Gut, November 2004
—
BACKGROUND AND AIMS: To explore the association between chronic cannabis abuse and a cyclical vomiting illness that presented in a series of cases in South Australia. METHODS: Nineteen patients were identified with chronic cannabis abuse and a cyclical vomiting illness. For le…
The endocannabinoid-CB(1) receptor system in pre- and postnatal life.
Authors: Ester Fride
European Journal of Pharmacology, October 2004
—
Recent research suggests that the endogenous cannabinoids (“endocannabinoids”) and their cannabinoid receptors have a major influence during pre- and postnatal development. First, high levels of the endocannaboid anandamide and cannabinoid receptors are present in the preimpla…
Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro.
Authors: Maria M. Medveczky, Tracy A. Sherwood, Thomas W. Klein, Herman Friedman, Peter G. Medveczky
BMC Medicinevolume, 15 September 2004
—
BACKGROUND: The major psychoactive cannabinoid compound of marijuana, delta-9 tetrahydrocannabinol (THC), has been shown to modulate immune responses and lymphocyte function. After primary infection the viral DNA genome of gamma herpesviruses persists in lymphoid cell nuclei i…
Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.
Authors: Katerina Venderova, Evzen Růzicka, Viktor Vorısek, Peter Visnovsky
Movement Disorders, September 2004
—
An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
Authors: C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler
Multiple Sclerosis Journal, 1 August 2004
—
The majority of patients with multiple sclerosis (MS) develop troublesome lower urinary tract symptoms (LUTS). Anecdotal reports suggest that cannabis may alleviate LUTS, and cannabinoid receptors in the bladder and nervous system are potential pharmacological targets. In an o…
Prenatal marijuana and alcohol exposure and academic achievement at age 10.
Authors: Lidush Goldschmidt, Gale A Richardson, Marie D Cornelius, Nancy L Day
Neurotoxicology and Teratology, July-August 2004
—
The effects of prenatal marijuana and alcohol exposure on school achievement at 10 years of age were examined. Women were interviewed about their substance use at the end of each trimester of pregnancy, at 8 and 18 months, and at 3, 6, 10, 14, and 16 years. The women were of l…